院外心脏骤停复苏期间给予亚硝酸钠对入院存活率的影响:一项随机临床试验
这项双盲、安慰剂对照的2期随机临床试验纳入美国华盛顿州金县1502例院外心脏骤停成人患者(平均年龄64岁,34%为女性),由急救人员在进行复苏时按1:1:1随机给予45 mg亚硝酸钠(n=500)、60 mg亚硝酸钠(n=498)或安慰剂(n=499)单次静脉推注。主要终点入院存活率:45 mg组205例(41%)、60 mg组212例(43%)、安慰剂组218例(44%),45 mg组与安慰剂组平均差异-2.9%(单侧95%CI -8.0%至∞;P=0.82),60 mg组与安慰剂组平均差异-1.3%(单侧95%CI -6.5%至∞;P=0.66),均未达统计学显著。7项预设次要终点均无显著差异,包括出院存活率(45 mg组13.2%、60 mg组14.5%、安慰剂组14.9%)。作者结论认为这些发现不支持在院外心脏骤停复苏中使用亚硝酸钠。
要点
- 院外心脏骤停成人患者复苏期间由急救人员静脉推注亚硝酸钠45 mg或60 mg,入院存活率与安慰剂相比无显著差异(45 mg组41% vs 安慰剂组44%,平均差异-2.9%,单侧95%CI -8.0%至∞,P=0.82)。
- 60 mg亚硝酸钠组入院存活率43% vs 安慰剂组44%,平均差异-1.3%(单侧95%CI -6.5%至∞,P=0.66),未达统计学显著。
- 出院存活率:45 mg组13.2%、60 mg组14.5%、安慰剂组14.9%;45 mg vs 安慰剂平均差异-1.7%(双侧95%CI -6.0%至2.6%,P=0.44),60 mg vs 安慰剂平均差异-0.4%(双侧95%CI -4.9%至4.0%,P=0.85)。
- 7项预设次要终点(包括自主循环恢复率、再骤停率、去甲肾上腺素使用、出院神经功能、24/48/72小时累积存活及ICU住院天数)均无显著差异。
- 作者结论认为这些发现不支持在院外心脏骤停复苏中使用亚硝酸钠。
适用人群与场景
- 美国华盛顿州金县1502例院外心脏骤停成人患者,包括心室颤动和非心室颤动心律,由急救人员进行复苏,2018年2月8日至2019年8月19日入组。
处置流程与药物剂量
- 符合条件的院外心脏骤停患者按1:1:1随机接受45 mg亚硝酸钠(n=500)、60 mg亚硝酸钠(n=498)或安慰剂(n=499),由急救人员在积极复苏期间尽早经静脉推注给药。
研究设计与关键结果
- 双盲、安慰剂对照、2期随机临床试验,纳入1502例院外心脏骤停成人患者(平均年龄64岁,标准差17岁;34%为女性),99%完成试验。
- 主要终点入院存活率:45 mg亚硝酸钠组205例(41%)、60 mg亚硝酸钠组212例(43%)、安慰剂组218例(44%);45 mg组 vs 安慰剂组平均差异-2.9%(单侧95%CI -8.0%至∞;P=0.82),60 mg组 vs 安慰剂组平均差异-1.3%(单侧95%CI -6.5%至∞;P=0.66)。
- 出院存活率:45 mg组66例(13.2%)、60 mg组72例(14.5%)、安慰剂组74例(14.9%);45 mg组 vs 安慰剂组平均差异-1.7%(双侧95%CI -6.0%至2.6%;P=0.44),60 mg组 vs 安慰剂组平均差异-0.4%(双侧95%CI -4.9%至4.0%;P=0.85)。
- 7项预设次要终点均无显著差异,包括自主循环恢复率、再骤停率、使用去甲肾上腺素支持血压、出院神经功能、24/48/72小时累积存活及ICU住院天数。
证据类型、等级与局限
- 证据类型:双盲、安慰剂对照、2期随机临床试验(ClinicalTrials.gov注册号NCT03452917)。
对床旁实践的改变
- 作者结论认为这些发现不支持在院外心脏骤停复苏中使用亚硝酸钠。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Therapeutic delivery of sodium nitrite during resuscitation improved survival in animal models of cardiac arrest, but efficacy has not been evaluated in clinical trials in humans.
OBJECTIVE: To determine whether parenteral administration of sodium nitrite given by paramedics during resuscitation for out-of-hospital cardiac arrest improved survival to hospital admission.
DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled, phase 2 randomized clinical trial including 1502 adults in King County, Washington, with out-of-hospital cardiac arrest from ventricular fibrillation or nonventricular fibrillation. Patients underwent resuscitation by paramedics and were enrolled between February 8, 2018, and August 19, 2019; follow-up and data abstraction were completed by December 31, 2019.
INTERVENTIONS: Eligible patients with out-of-hospital cardiac arrest were randomized (1:1:1) to receive 45 mg of sodium nitrite (n = 500), 60 mg of sodium nitrite (n = 498), or placebo (n = 499), which was given via bolus injection by the paramedics as soon as possible during active resuscitation.
MAIN OUTCOMES AND MEASURES: The primary outcome was survival to hospital admission and was evaluated with 1-sided hypothesis testing. The secondary outcomes included out-of-hospital variables (rate of return of spontaneous circulation, rate of rearrest, and use of norepinephrine to support blood pressure) and in-hospital variables (survival to hospital discharge; neurological outcomes at hospital discharge; cumulative survival to 24 hours, 48 hours, and 72 hours; and number of days in the intensive care unit).
RESULTS: Among 1502 patients with out-of-hospital cardiac arrest who were randomized (mean age, 64 years [SD, 17 years]; 34% were women), 99% completed the trial. Overall, 205 patients (41%) in the 45 mg of sodium nitrite group and 212 patients (43%) in the 60 mg of sodium nitrite group compared with 218 patients (44%) in the placebo group survived to hospital admission; the mean difference for the 45-mg dose vs placebo was -2.9% (1-sided 95% CI, -8.0% to ∞; P = .82) and the mean difference for the 60-mg dose vs placebo was -1.3% (1-sided 95% CI, -6.5% to ∞; P = .66). None of the 7 prespecified secondary outcomes were significantly different, including survival to hospital discharge for 66 patients (13.2%) in the 45 mg of sodium nitrite group and 72 patients (14.5%) in the 60 mg of sodium nitrite group compared with 74 patients (14.9%) in the placebo group; the mean difference for the 45-mg dose vs placebo was -1.7% (2-sided 95% CI, -6.0% to 2.6%; P = .44) and the mean difference for the 60-mg dose vs placebo was -0.4% (2-sided 95% CI, -4.9% to 4.0%; P = .85).
CONCLUSIONS AND RELEVANCE: Among patients with out-of-hospital cardiac arrest, administration of sodium nitrite, compared with placebo, did not significantly improve survival to hospital admission. These findings do not support the use of sodium nitrite during resuscitation from out-of-hospital cardiac arrest.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03452917.
参考来源
- Kim F, Maynard C, Dezfulian C, et al. Effect of Out-of-Hospital Sodium Nitrite on Survival to Hospital Admission After Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2021. PMID: 33433575. doi:10.1001/jama.2020.24326
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。